• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Arch Rheumatol . Pandemic of the century: COVID-19 in inflammatory rheumatic diseases of a national cohort with 3,532 patients

tetano

Editor, Senior Moderator
Arch Rheumatol


. 2024 Mar 22;39(2):203-212.
doi: 10.46497/ArchRheumatol.2024.10313. eCollection 2024 Jun. Pandemic of the century: COVID-19 in inflammatory rheumatic diseases of a national cohort with 3,532 patients

Fatma Yurdakul[SUP] 1 [/SUP], Hatice Bodur[SUP] 2 [/SUP], Ahmet Kıvanç Cengiz[SUP] 3 [/SUP], Yunus Durmaz[SUP] 4 [/SUP], Mehmet Tuncay Duruöz[SUP] 5 [/SUP], Taciser Kaya[SUP] 6 [/SUP], Sertaç Ketenci[SUP] 3 [/SUP], Nihan Cüzdan[SUP] 7 [/SUP], Tuba Güler[SUP] 1 [/SUP], Zafer Günendi[SUP] 8 [/SUP], Selda Sarıkaya[SUP] 9 [/SUP], Erhan Çapkın[SUP] 10 [/SUP], Mustafa Erkut Önder[SUP] 11 [/SUP], Meltem Alkan Melikoğlu[SUP] 12 [/SUP], Rengin Güzel[SUP] 13 [/SUP], Nesrin Şen[SUP] 14 [/SUP], Ata Bora Ayna[SUP] 15 [/SUP], Özgür Akgül[SUP] 16 [/SUP], Erhan Eser[SUP] 17 [/SUP], Şebnem Ataman[SUP] 18 [/SUP]



Affiliations
Abstract

Objectives: This study aimed to assess the clinical outcomes and risk factors for severe coronavirus disease 2019 (COVID-19) in patients with inflammatory rheumatic disease (IRD) of a national cohort.
Patients and methods: The multicenter cross-sectional study was carried out between July 15, 2020, and February 28, 2021. Data collection was provided from a national network database system, and 3,532 IRD patients (2,359 males, 1,173 females; mean age: 48.7±13.9 years; range; 18 to 90 years) were analyzed. Demographics, clinics about rheumatic disease, comorbidities, smoking status, being infected with COVID-19, and the course of the infection were questioned by rheumatology specialists.
Results: One hundred seventeen patients were infected with COVID-19, the hospitalization rate due to COVID-19 was 58.9%, and the mortality rate was 1.7%. There was no difference between the COVID-19 positive and negative groups in terms of rheumatic disease activities and receiving drugs. It was observed that patients with COVID-19 had worse compliance with isolation rules, and bacillus Calmette-Guérin (BCG) vaccination was less common. The mean age and the rate of smoking of hospitalized COVID-19 patients were higher than those without hospitalization.
Conclusion: In this cohort, in which real-life data were analyzed, COVID-19 rates in IRD patients were similar to the general population for the same period. Compliance with the isolation rules and BCG vaccination attracted attention as components that reduce the risk of COVID-19 infection. The risk factors for hospitalization were older age and smoking.

Keywords: Disease-modifying antirheumatic drugs; hospitalization; mortality rate; rheumatic diseases; severe acute respiratory syndrome coronavirus 2..

 
Back
Top Bottom